{
    "ASSETS": {
        "Current Assets": {
            "Cash and cash equivalents": [
                9123,
                13979
            ],
            "Marketable debt securities": [
                130,
                2987
            ],
            "Receivables": [
                9886,
                9369
            ],
            "Inventories": [
                2339,
                2095
            ],
            "Other current assets": [
                5795,
                4832
            ],
            "Total Current Assets": [
                27273,
                33262
            ]
        },
        "Property, plant and equipment": [
            6255,
            6049
        ],
        "Goodwill": [
            21149,
            20502
        ],
        "Other intangible assets": [
            35859,
            42527
        ],
        "Deferred income taxes": [
            1344,
            1439
        ],
        "Other non-current assets": [
            4940,
            5535
        ],
        "Total Assets": [
            96820,
            109314
        ]
    },
    "LIABILITIES": {
        "Current Liabilities": {
            "Short-term debt obligations": [
                4264,
                4948
            ],
            "Accounts payable": [
                3040,
                2949
            ],
            "Other current liabilities": [
                14586,
                13971
            ],
            "Total Current Liabilities": [
                21890,
                21868
            ]
        },
        "Deferred income taxes": [
            2166,
            4501
        ],
        "Long-term debt": [
            35056,
            39605
        ],
        "Other non-current liabilities": [
            6590,
            7334
        ],
        "Total Liabilities": [
            65702,
            73308
        ],
        "Commitments and contingencies": null
    },
    "EQUITY": {
        "Bristol-Myers Squibb Company Shareholders Equity": {
            "Preferred stock, $2 convertible series, par value $ 1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $ 50 per share": [
                0,
                0
            ],
            "Common stock, par value of $ 0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021": [
                292,
                292
            ],
            "Capital in excess of par value of stock": [
                45165,
                44361
            ],
            "Accumulated other comprehensive loss": [
                -1281,
                -1268
            ],
            "Retained earnings": [
                25503,
                23820
            ],
            "Less cost of treasury stock 825 million common shares in 2022 and 747 million common shares in 2021": [
                -38618,
                -31259
            ],
            "Total Bristol-Myers Squibb Company Shareholders Equity": [
                31061,
                35946
            ]
        },
        "Noncontrolling interest": [
            57,
            60
        ],
        "Total Equity": [
            31118,
            36006
        ]
    },
    "Total Liabilities and Equity": [
        96820,
        109314
    ]
}